425: SL Science Holding Adds Directors for SPAC Merger

Horizon Space Acquisition II Corp. (HSPT) announced two new independent director nominees for SL Science Holding Limited (PubCo) ahead of its business combination with SL BIO Ltd., updating beneficial ownership details.

Summary

• HSPT filed a Form 425 to supplement its definitive proxy statement for the proposed business combination with SL BIO Ltd., forming SL Science Holding Limited (PubCo).
• PubCo will add two new independent director nominees: Joseph Levinson and Qian (Hebe) Xu.
• Joseph Levinson has over 25 years of experience in cross-border issues for U.S.-listed foreign companies and accounting, holding a U.S. Certified Public Accountant license.
• Qian (Hebe) Xu, currently an independent director of HSPT, has over 15 years of experience in financial markets, specializing in US-China cross-border transactions.
• Neither Joseph Levinson nor Qian (Hebe) Xu will serve as a member of PubCo's board committees.
• The beneficial ownership table for PubCo ordinary shares immediately following the business combination has been updated.
• In a no-redemption scenario, 566,591,350 PubCo Ordinary Shares are expected to be outstanding, with William Wang beneficially owning 58.9% (333,832,129 shares) and all director nominees and executive officers as a group owning 58.9% (333,852,129 shares).
• In a maximum-redemption scenario, 559,956,923 PubCo Ordinary Shares are expected to be outstanding, with William Wang beneficially owning 59.6% and all director nominees and executive officers as a group owning 59.6%.
• Qian (Hebe) Xu will beneficially own 20,000 PubCo Ordinary Shares, representing less than 1%.
• There are no changes to the Business Combination Meeting schedule, redemption deadline, location, record date, purpose, or any of the proposals to be acted upon.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as the strengthening of the board with experienced independent directors is a crucial step for corporate governance and investor confidence ahead of the business combination, despite the new directors not serving on committees.

Positives

• The addition of two experienced independent directors, Joseph Levinson and Qian (Hebe) Xu, enhances corporate governance and financial oversight for the combined entity.
• Joseph Levinson's background in accounting and managing cross-border issues for U.S.-listed foreign companies provides valuable expertise.
• Qian (Hebe) Xu's extensive experience in financial markets and US-China cross-border transactions strengthens the board's strategic capabilities.
• The business combination meeting schedule remains unchanged, indicating progress towards closing the transaction.

Negatives

• The new independent directors, Joseph Levinson and Qian (Hebe) Xu, will not serve on PubCo's board committees, which might limit their direct influence on specific governance functions.
• William Wang, CEO, Director, and Chairman, will beneficially own a significant majority (58.9% to 59.6%) of PubCo's voting power, which could raise concerns about minority shareholder influence.

Risks

• The combined company's limited operating history.
• The ability of SL Bio or the combined company to identify and integrate acquisitions.
• General economic and market conditions impacting demand for the products of SL Bio or the combined company.
• The inability to complete the proposed Business Combination.
• The inability to recognize the anticipated benefits of the proposed Business Combination, which may be affected by the amount of cash available following any redemptions by HSPT's shareholders.
• The ability to meet stock exchange listing standards following the consummation of the proposed Business Combination.
• Costs related to the proposed Business Combination.
• The possibility that the proposed Business Combination does not close, including due to the failure to receive required security holder approvals, or the failure of other closing conditions.

Future Outlook

The combined entity, SL Science Holding Limited (PubCo), expects its executive compensation program to reflect SL Bio's policies and philosophies, as they may be modified and updated. Decisions with respect to executive officer compensation will be made by the compensation committee of PubCo's board of directors. PubCo's non-executive independent directors will be entitled to compensation commensurate with their respective duties and experience, including annual or monthly cash retainers, reimbursement of reasonable expenses, and, for certain independent directors, equity-based awards pursuant to an equity compensation plan to be adopted following the consummation of the Business Combination.

Management Comments

• SL Science Holding Limited believes that the background and experience of the new independent directors will be a significant asset to the Company.
• SL Science Holding Limited looks forward to the participation of the new independent directors on the Board.

Industry Context

StockSavvy.ai notes that the addition of independent directors with strong financial and cross-border experience is a common practice for SPACs nearing a de-SPAC transaction, aiming to bolster corporate governance and investor confidence, especially for companies with international operations or aspirations. This move aligns with market expectations for enhanced oversight as a company transitions to public trading.

Comparison to Industry Standards

• The appointment of independent directors with significant financial and public company experience, such as Joseph Levinson (former director at Nasdaq-listed AIIO and CLEU) and Qian (Hebe) Xu (current director at Nasdaq-listed HLP), aligns with best practices for corporate governance in U.S.-listed companies.
• The beneficial ownership structure, where the CEO holds a majority stake (58.9%-59.6%), is higher than the average for many publicly traded companies, which often aim for a more dispersed ownership to enhance independent board oversight, though it is not uncommon in founder-led companies or those transitioning from private ownership.
• The provision for non-executive independent directors to receive cash retainers and equity-based awards is standard practice in the industry to attract and retain qualified board members.

Management Changes

Corporate Governance

Related Party Transactions

• On January 5, 2026, SL Link Co., Ltd., a company controlled by William Wang, purchased 30,000 ordinary shares of SL Bio from an individual shareholder at a purchase price of US$66.67 per share.
• William Wang's equity interest in PubCo will be beneficially owned through SL Link Holding Ltd. (owned equally by Mr. Wang and his spouse) and SL Link Co., Ltd. (controlled by Mr. Wang).

Stakeholder Impact

• Shareholders: The addition of experienced independent directors may increase investor confidence in corporate governance. The updated beneficial ownership table provides clarity on the post-merger ownership structure, particularly the significant stake held by William Wang.
• Management: The executive compensation program will be aligned with SL Bio's policies, and a compensation committee will oversee decisions.
• Directors: New independent directors will receive compensation including cash retainers and potential equity awards, attracting qualified individuals.

Next Steps

• The Business Combination Meeting of HSPT's shareholders will be held on February 12, 2026, at 9:00 a.m. Eastern Time.
• Shareholders who have not yet voted are encouraged to do so as soon as possible.
• Following the closing of the Business Combination, PubCo expects to adopt an equity compensation plan.
• Decisions regarding executive compensation will be made by PubCo's compensation committee after the Business Combination closes.

Key Dates

Recommendation

The filing provides a procedural update regarding the addition of independent directors and an updated beneficial ownership table ahead of the business combination. While the strengthening of corporate governance is a positive, there are no new financial or operational details to significantly alter the investment thesis. The concentrated ownership by the CEO is a factor to consider. Therefore, a 'hold' recommendation is appropriate as investors await the completion of the merger and subsequent operational performance.

Keywords

SL Science Holding Limited, Horizon Space Acquisition II Corp., SL BIO Ltd., SPAC, Business Combination, Merger, Independent Directors, Corporate Governance, Proxy Statement, SEC Filing, Beneficial Ownership, Nasdaq